盐酸米托蒽醌治疗恶性肿瘤的近期疗效  

Mitoxan trone in the Treatment of Malignancies

作　　者：付波[1] 谢名英[2] 洪元康[2] 梅治家[2] 吴谨绪[2] 朱焕玲[2] 张应潮[3] 叶乃谣 丁梅君[4] 贺明谌 宫秀清[6] 郑金娣[6] 

机构地区：[1]华西医科大 [2]华西医科大学附一院 [3]四川省肿瘤医院 [4]四川省人民医院 [5]成都市第三人民医院 [6]重庆市肿瘤研究所

出　　处：《华西医学》1992年第4期479-482,共4页West China Medical Journal

摘　　要：应用国产盐酸米托蒽醌注射液单药和组成联合化疗方案治疗各类恶性肿瘤230例,在可评定疗效的218例中,白血病单药有效率43.8％,联合化疗有效率81.8％;恶性淋巴瘤单药有效率61％,联合化疗有效率65.5％;乳腺癌单药有效率34.6％,联合化疗有效率50％。主要毒副作用是白细胞减少,未见严重的心脏毒性。我们认为米托蒽醌是一有效的、值得临床推广应用的抗肿瘤药。Two hundred thirty patients with variou stypes of malignancies treated by single mitoxantrone (DHAQ) or combined chemotherapy were reported. Of these 230 patients 218 were evaluable. The total response rate to leukemia was 43.8% for the single agent and. 81.8% for the combicd chemotherapy containing DHAQ, Ara-c, VCR and Pred. The total respose rate to malignant lymphoma was 61% for the single agent and 65.5% for the combined chemotherapy containing DHAQ, VCR, CTX and pred. The respose rate in patients with breast cancer was 34.6% treated by single agent and 50% treated by combinated chemotherapy containing DHAQ, 5-FU and VCR. Drug-induced side effects included leukopenia. No severe cardiotoxicity was seen in this study. we suggested that DHAQ was an effective antitumor drug.

关 键 词：米托蒽醌 白血病 癌 药物疗法 

分 类 号：R730.5[医药卫生—肿瘤]